ERBITUX® (Cetuximab) – product of Merck KGaA and ImClone Systems Inc. – has received EU backing as first-line treatment for colon cancer.
According to the European Medicines Agency:
Erbitux can be given as the first drug in colon-cancer treatment in patients who carry an unmutated kras gene, restricting its use to about 65 percent of patients.
Erbitux is the first monoclonal antibody approved by the US FDA for the treatment of advanced colon cancer that has spread to the other parts of the body — either alone or in combination with other treatments.
Read more about the EU backing on Erbitux from Bloomberg.